{"name":"Harbour BioMed","slug":"harbour-biomed","ticker":"2142.HK","exchange":"HKEX","domain":"harbourbiomed.com","description":"HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for treating myasthenia gravis; Porustobart HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4 for treating melanoma, colorectal cancer, hepatocellular carcinoma, and neuroendocrine neoplasm. It is also developing HBM7020 for treating hematologic carcinoma and autoimmune diseases; HBM9378 for the treatment of asthma and chronic obstructive pulmonary disease; and HBM1020, HBM1022, HBM9014, HBM7022, HBM7008, HBM9027","hq":"Suzhou, China","founded":0,"employees":"272","ceo":"Jingsong Wang","sector":"Immunology / Bispecific Antibodies","stockPrice":12.73,"stockChange":-0.06,"stockChangePercent":-0.47,"marketCap":"$10.7B","metrics":{"revenue":157975008,"revenueGrowth":293.5,"grossMargin":94.5,"rdSpend":0,"netIncome":91333000,"cash":403056000,"dividendYield":0,"peRatio":13.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"HB208 patent cliff ($0.0B at risk)","drug":"HB208","type":"patent_expiry","sentiment":"negative"},{"date":"2033-06-01","label":"HB212 patent cliff ($0.0B at risk)","drug":"HB212","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"HBM4003 and pembrolizumab","genericName":"HBM4003 and pembrolizumab","slug":"hbm4003-and-pembrolizumab","indication":"Other","status":"phase_1"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"HBM9036 0.25% Ophthalmic Solution","genericName":"HBM9036 0.25% Ophthalmic Solution","slug":"hbm9036-0-25-ophthalmic-solution","indication":"Dry eye disease","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"HBM9161 Injection (680mg)","genericName":"HBM9161 Injection (680mg)","slug":"hbm9161-injection-680mg","indication":"Non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"HBM4003 and pembrolizumab","genericName":"HBM4003 and pembrolizumab","slug":"hbm4003-and-pembrolizumab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HBM9036 0.25% Ophthalmic Solution","genericName":"HBM9036 0.25% Ophthalmic Solution","slug":"hbm9036-0-25-ophthalmic-solution","phase":"phase_3","mechanism":"HBM9036 is a small-molecule inhibitor of the C5a receptor that reduces complement-mediated inflammation in the eye.","indications":["Dry eye disease"],"catalyst":""},{"name":"HBM9161 Injection (680mg)","genericName":"HBM9161 Injection (680mg)","slug":"hbm9161-injection-680mg","phase":"phase_3","mechanism":"HBM9161 is a monoclonal antibody that blocks the interaction between PD-L1 and its receptors to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""}],"recentEvents":[{"date":"2024-08-28","type":"regulatory","headline":"Harbour BioMed Announces FDA Clearance for Phase 1 Clinical Trial of HB208","summary":"Harbour BioMed has received FDA clearance to initiate a Phase 1 clinical trial for its bispecific antibody candidate, HB208, in the treatment of non-Hodgkin lymphoma.","drugName":"HB208","sentiment":"positive"},{"date":"2024-05-15","type":"earnings","headline":"Harbour BioMed Reports First Quarter 2024 Financial Results","summary":"Harbour BioMed has reported its financial results for the first quarter of 2024, with revenue increasing by 25% year-over-year.","drugName":"","sentiment":"neutral"},{"date":"2023-12-20","type":"deal","headline":"Harbour BioMed Enters into Licensing Agreement with [Partner Company]","summary":"Harbour BioMed has entered into a licensing agreement with [Partner Company] to develop and commercialize its bispecific antibody candidates in certain regions.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQZnFmQjMwTXhMWU1pQnphb3JPcUl0QXgtc1dXRm5ZMGxUUXVIVDYxY2dvWGdNQ3M4MGlYNjFKOFVnLVlTYThfSDUycl9KdGhDNXNaaU9vbEtmY21vUE5XV0gweFExc00tWUh3emcxcW85QlMtaGpfNXZrMVo2bE1Dc0ZMVm81cEt0OFE?oc=5","date":"2025-09-02","type":"pipeline","source":"富途牛牛","summary":"Why did GIC and AZ place dual bets on HBM Holdings Limited (2142.HK) to become a \"scarce asset\" in the innovative drug sector? - 富途牛牛","headline":"Why did GIC and AZ place dual bets on HBM Holdings Limited (2142.HK) to become a \"scarce asset\" in the innovative drug s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPY3hPbGhvWGYwUjVpblVXMEd3eWVCWVdyOVZOUTRHRDNOemQwOHprRWptTlJWckRTOUVKbWRMWENmN0FtcjVQV2tYOVhNWS1Pb2xZWnpNRUIzV0tib0tSVXdGaUQ5bDFpM250MlQzUDEyb0JoY0JlRFRMOG5DVThWSV9tZ3pEM1ZYNUlJd1dWVVpYTml6LTQtbzF0Ml9mRVZ5YTZKZGZ3?oc=5","date":"2025-03-04","type":"deal","source":"BioWorld News","summary":"Harbour Biomed newco HBM Alpha pens $395M hyperplasia drug deal - BioWorld News","headline":"Harbour Biomed newco HBM Alpha pens $395M hyperplasia drug deal","sentiment":"neutral"}],"patents":[{"drugName":"HB208","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0},{"drugName":"HB212","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2033-06-01","territory":"US","annualRevenue":0}],"drugCount":3,"phaseCounts":{"phase_1":1,"phase_3":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["BeiGene","Innovent Biologics","Sino Biopharmaceutical"],"therapeuticFocus":["Immunotherapy","Oncology"],"financials":{"source":"yahoo_finance","revenue":157975000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":157975000},{"period":"2024-12-31","value":38100000},{"period":"2023-12-31","value":89502000},{"period":"2022-12-31","value":40659000}],"grossProfit":149244000,"grossProfitHistory":[{"period":"2025-12-31","value":149244000},{"period":"2024-12-31","value":33614000},{"period":"2023-12-31","value":87468000},{"period":"2022-12-31","value":40529000}],"rdSpend":39765000,"rdSpendHistory":[{"period":"2025-12-31","value":39765000},{"period":"2024-12-31","value":20999000},{"period":"2023-12-31","value":45081000},{"period":"2022-12-31","value":135143000}],"sgaSpend":15703000,"operatingIncome":82378000,"operatingIncomeHistory":[{"period":"2025-12-31","value":82378000},{"period":"2024-12-31","value":-2185000},{"period":"2023-12-31","value":22667000},{"period":"2022-12-31","value":-121327000}],"netIncome":91333000,"netIncomeHistory":[{"period":"2025-12-31","value":91333000},{"period":"2024-12-31","value":2778000},{"period":"2023-12-31","value":22797000},{"period":"2022-12-31","value":-137222000}],"eps":0.12,"epsHistory":[{"period":"2025-12-31","value":0.12},{"period":"2024-12-31","value":0.0037},{"period":"2023-12-31","value":0.03},{"period":"2022-12-31","value":-0.19}],"cash":401898000,"cashHistory":[{"period":"2025-12-31","value":401898000},{"period":"2024-12-31","value":165940000},{"period":"2023-12-31","value":140324000},{"period":"2022-12-31","value":171705000}],"totalAssets":500256000,"totalLiabilities":133144000,"totalDebt":81769000,"equity":367125000,"operatingCashflow":81334000,"operatingCashflowHistory":[{"period":"2025-12-31","value":81334000},{"period":"2024-12-31","value":30676000},{"period":"2023-12-31","value":-19122000},{"period":"2022-12-31","value":-99964000}],"capex":-11753000,"capexHistory":[{"period":"2025-12-31","value":-11753000},{"period":"2024-12-31","value":-235000},{"period":"2023-12-31","value":-2480000},{"period":"2022-12-31","value":-18438000}],"freeCashflow":69581000,"dividendsPaid":null,"buybacks":-25082000,"employees":272,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":12.73,"previousClose":12.79,"fiftyTwoWeekHigh":17.98,"fiftyTwoWeekLow":7.52,"fiftyTwoWeekRange":"7.52 - 17.98","fiftyDayAverage":13.15,"twoHundredDayAverage":13.17,"beta":1.4,"enterpriseValue":10321122304,"forwardPE":17,"priceToBook":3.7,"priceToSales":67.48,"enterpriseToRevenue":65.33,"enterpriseToEbitda":126.49,"pegRatio":0,"ebitda":81598000,"ebitdaMargin":51.7,"freeCashflow":44419124,"operatingCashflow":81334000,"totalDebt":81769000,"debtToEquity":22.3,"currentRatio":5.17,"returnOnAssets":14.1,"returnOnEquity":37.6,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":19.99,"targetHighPrice":19.99,"targetLowPrice":19.99,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":21,"institutionHeldPercent":23.3,"sharesOutstanding":837448362,"floatShares":529587991,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0.94,"epsForward":0.75,"revenuePerShare":0.2,"bookValue":3.44,"officers":[{"age":60,"name":"Dr. Jingsong  Wang M.D., Ph.D.","title":"Founder, Chairman & CEO"},{"age":48,"name":"Dr. Yiping  Rong Ph.D.","title":"Chief Scientific Officer & Executive Director"},{"age":null,"name":"Dr. C. Adam Zong MBA, Ph.D.","title":"President"},{"age":null,"name":"Mr. Youchen  Chen","title":"VP, CFO & Investor Relations"},{"age":null,"name":"Dr. Ian Y.  Liu","title":"Senior VP & Global Head of Legal and Joint Company Secretary"},{"age":null,"name":"Dr. Peter F. Moesta Ph.D.","title":"Member of Scientific Advisory Board & Chief CMC Advisor"},{"age":50,"name":"Dr. Xiaolu  Tao","title":"Chief Development Officer"},{"age":null,"name":"Dr. Steve  Arkinstall DPhil","title":"Chief Scientific Advisor"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.harbourbiomed.com","phone":"86 512 6579 0025"}}